abstract: Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.

Br J Clin Pharmacol. 2012 Apr 3

Abstract

Aim: 
Animal and in vitro studies suggest that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk for ovarian cancer; however, results from these studies have been inconsistent. The aim of our study is to review and summarize the evidence provided by longitudinal studies on the association between NSAID use and ovarian cancer risk.

Methods:
A comprehensive literature search for articles published up to December 2011 was performed. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Relative risk (RR) or odds ratio (OR) were calculated.


Conclusions: 
Our findings indicate that there is no strong evidence of an association between Aspirin/NA-NSAID use and ovarian cancer. However, this subject deserves further investigation.

abstract: Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer.

BACKGROUND:

Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) and acetaminophen all have biologic effects that might reduce the risk of ovarian cancer. However, epidemiologic data on this question are mixed.

CONCLUSIONS:

Risk reductions of ovarian cancer were observed with use of aspirin or selective cyclooxygenase-2 inhibitors. However, the results should be interpreted with caution due to the inherent study limitations and biases.

Registry Data Point to Diclofenac as Deadliest NSAID

Note: discusses adverse/risks of numerous NSAID's

Nonsteroidal Anti-Inflammatory Drugs and Risk for Ovarian and Endometrial Cancers in the Iowa Women's Health Study — Cancer Epidemiology, Biomarkers & Prevention